Страна: Канада
мова: англійська
Джерело: Health Canada
VARENICLINE (VARENICLINE TARTRATE); VARENICLINE (VARENICLINE TARTRATE)
APOTEX INC
N07BA03
VARENICLINE
0.5MG; 1MG
KIT
VARENICLINE (VARENICLINE TARTRATE) 0.5MG; VARENICLINE (VARENICLINE TARTRATE) 1MG
ORAL
11(0.5MG) & 14(1MG)
Prescription
MISCELLANEOUS AUTONOMIC DRUGS
Active ingredient group (AIG) number: 0252269001; AHFS:
APPROVED
2018-02-02
_APO-VARENICLINE PRODUCT MONOGRAPH_ _ _ _ _ _ _ _PAGE 1 OF 59_ _ _ PRODUCT MONOGRAPH PR APO-VARENICLINE VARENICLINE TABLETS 0.5 MG AND 1 MG VARENICLINE (AS VARENICLINE TARTRATE) SMOKING-CESSATION AID APOTEX INC. DATE OF REVISION: 150 SIGNET DRIVE April 9, 2019 TORONTO, ONTARIO M9L 1T9 SUBMISSION CONTROL NUMBER: 226339 _APO-VARENICLINE PRODUCT MONOGRAPH_ _ _ _ _ _ _ _PAGE 2 OF 59_ _ _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ....................................................... 3 SUMMARY PRODUCT INFORMATION ............................................................................. 3 INDICATIONS AND CLINICAL USE ................................................................................... 3 CONTRAINDICATIONS ........................................................................................................ 3 WARNINGS AND PRECAUTIONS ....................................................................................... 4 ADVERSE REACTIONS ....................................................................................................... 12 DRUG INTERACTIONS ....................................................................................................... 24 DOSAGE AND ADMINISTRATION ................................................................................... 26 OVERDOSAGE ...................................................................................................................... 29 ACTION AND CLINICAL PHARMACOLOGY ................................................................. 30 STORAGE AND STABILITY ............................................................................................... 38 DOSAGE FORMS, COMPOSITION AND PACKAGING .................................................. 39 PART II: SCIENTIFIC INFORMATION .............................................................................. 40 PHARMACEUTICAL INFORMATION ............................................................................... 40 CLINICAL TRIALS ............................. Прочитайте повний документ